These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8220401)

  • 21. Issues in designing flexible trials.
    Posch M; Bauer P; Brannath W
    Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variance estimation in clinical studies with interim sample size re-estimation.
    Miller F
    Biometrics; 2005 Jun; 61(2):355-61. PubMed ID: 16011681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sequential procedure for monitoring clinical trials against historical controls.
    Xiong X; Tan M; Boyett J
    Stat Med; 2007 Mar; 26(7):1497-511. PubMed ID: 16900551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal two-stage designs for clinical trials based on safety and efficacy.
    Thall PF; Cheng SC
    Stat Med; 2001 Apr; 20(7):1023-32. PubMed ID: 11276033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive group sequential test for clinical trials with changing patient population.
    Feng H; Shao J; Chow SC
    J Biopharm Stat; 2007; 17(6):1227-38. PubMed ID: 18027228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size reestimation by Bayesian prediction.
    Wang MD
    Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential boundaries approach in clinical trials with unequal allocation ratios.
    Jafari P; Ayatollahi SM; Behboodian J
    BMC Med Res Methodol; 2006 Jan; 6():1. PubMed ID: 16412232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for including patients recruited during interim analysis of clinical trials.
    Faldum A; Hommel G
    J Biopharm Stat; 2007; 17(6):1211-25. PubMed ID: 18027227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Test for the consistency of noninferiority from multiple clinical trials.
    Yan X; Wang MC; Su X
    J Biopharm Stat; 2007; 17(2):265-78. PubMed ID: 17365223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A mixture gatekeeping procedure based on the Hommel test for clinical trial applications.
    Brechenmacher T; Xu J; Dmitrienko A; Tamhane AC
    J Biopharm Stat; 2011 Jul; 21(4):748-67. PubMed ID: 21516567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring a three-armed clinical trial with survival endpoints: Fisher's least significant difference approach.
    Chen PL; Dominik R
    J Biopharm Stat; 2004 Aug; 14(3):791-801. PubMed ID: 15468765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population enrichment designs: case study of a large multinational trial.
    Mehta CR; Gao P
    J Biopharm Stat; 2011 Jul; 21(4):831-45. PubMed ID: 21516572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints.
    Jennison C; Turnbull BW
    Biometrics; 1993 Sep; 49(3):741-52. PubMed ID: 8241370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD; Emerson SS
    Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The use of state of the art statistical methodology in biomedical research: the example of methodology for interim analyses in clinical trials].
    Muñoz SR; Bangdiwala SI
    Rev Med Chil; 2001 Sep; 129(9):983-8. PubMed ID: 11725478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Robustness of sample size re-estimation procedure in clinical trials (arbitrary populations).
    Govindarajulu Z
    Stat Med; 2003 Jun; 22(11):1819-28. PubMed ID: 12754717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.